Y. Sugio et al., Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity, INT J HEMAT, 74(3), 2001, pp. 347-351
A 41-year-old Japanese man complained of a left-sided visual disturbance. I
maging by magnetic resonance angiography revealed a narrowing of the left i
nternal cervical artery. Thus, ticlopidine (Tc) administration was started
at a daily dose of 300 mg. However, 2 weeks later, severe thrombocytopenia,
fever, nausea, and psychiatric symptoms developed; Tc was therefore discon
tinued. Based on the diagnostic hallmark of 5 clinical signs, the patient's
disease was diagnosed as thrombotic thrombocytopenic purpura (TTP). Daily
plasmapheresis was performed for the first 4 days, and the patient's clinic
al signs gradually improved. Von Willebrand factor-cleaving protease (vWF-C
Pase) activity in his plasma was less than 3% of that of the control sample
at diagnosis, but that value recovered steadily following plasmapheresis.
In addition, immunaglobulin G purified from the patient plasma inhibited vW
F-CPase activity in normal plasma with a specific activity of 0.8 Bethesda
units/mg. No sign of TTP relapse has been noted following cessation of Tc.
Thus, it was concluded that the patient developed TTP by producing an inhib
itory autoantibody against vWF-CPase activity that was presumably triggered
by Tc administration. (C) 2001 The Japanese Society of Hematology.